Unlabelled: Extensive and escalating research has been directed towards halozymes derived from halophiles thriving in extreme hypersaline environments, owing to their myriad industrial applications. These extremophiles have evolved various physiological and metabolic adaptations to endure such extremes, enhancing their industrial potential. Being a potential source of lipases, halophiles of extreme niches have emerged as a emerging research area. This interest has been fueled by the recognition that extreme environments serve as rich reservoirs of diverse cold-active alkaliphilic enzymes.
Methods: TKW3, isolated from brackish Lake Tso Kar of the Ladakh region, India, produced cold-adapted haloalkaliphilic lipase halozyme. The current study focused on the purification and biochemical characterisation of lipase derived from halophilic bacteria.
Results: The lipase enzyme, purified to homogeneity, exhibited a molecular mass of 28 kDa as confirmed by SDS-PAGE analysis. The purification process yielded a purification fold of 12.01 and a final recovery rate of 29.9%. It demonstrated optimal activity at 30 °C and pH 9. The enzyme was evaluated and demonstrated to exhibit stability over a broad temperature range spanning from 5 °C to 55 °C, as well as a wide pH range of 7.0 to 9.0. Due to its stability across a diverse spectrum of pH values, surfactants, metal ions, and inhibitors, the enzyme appeared to hold significant promise for application within the leather and detergent sectors. Upon undergoing detergent compatibility tests spanning diverse temperature ranges, the lipase showcased compatibility with various commercial detergents, thereby presenting itself as an attractive candidate for inclusion in detergent formulations within the industry.
Conclusions: The lipase from TKW3 exhibits promising attributes, including alkali stability, halophilicity, and a wide spectrum of substrate specificity, rendering it an attractive option for incorporation into detergent formulations within the detergent industry. As far as we are aware, this is the first report on the purification and characterization of lipase enzyme from bacterial halophiles in a Tso Kar brackish lake.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846503 | PMC |
http://dx.doi.org/10.7717/peerj.18921 | DOI Listing |
Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients.
View Article and Find Full Text PDFPeerJ
February 2025
School of Biotechnology, Shri Mata Vaishno Devi University, Katra, J&K, India.
Unlabelled: Extensive and escalating research has been directed towards halozymes derived from halophiles thriving in extreme hypersaline environments, owing to their myriad industrial applications. These extremophiles have evolved various physiological and metabolic adaptations to endure such extremes, enhancing their industrial potential. Being a potential source of lipases, halophiles of extreme niches have emerged as a emerging research area.
View Article and Find Full Text PDFBackground: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!